Sobi publishes report for the third quarter 2021
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent. July – September · Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER) · Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta® SEK 1,035 M (1,115), -6 per cent at CER, Alprolix® SEK 430 M (435), unchanged at CER, and Doptelet®